Peran pertanda tulang dalam serum pada tatalaksana osteoporosis

Article Sidebar

PDF
Published: 2007-09-27
DOI: https://doi.org/10.18051/UnivMed.2007.v26.152-159
Keywords:
Osteoporosis, pertanda tulang, osteocalcin, P1-NP, ß-CrossLaps

Main Article Content

Adi Priyana
Bagian Patologi Klinik Fakultas Kedokteran Universitas Trisakti

Abstract

Osteoporosis adalah kelainan tulang yang kronik progresif akibat berkurangnya massa dan kekuatan tulang sehingga menjadi predisposisi meningkatnya risiko fraktur. Pertanda tulang dapat memberikan gambaran proses remodelling yang sedang terjadi. Pemeriksaan ini meliputi pertanda resorpsi tulang yang dilakukan oleh osteoklas dan pertanda formasi tulang yang dilakukan oleh osteoblas. Diagnosis untuk osteoporosis yang dianggap baku adalah pemeriksaan bone mass density (BMD) tetapi BMD tidak dipakai untuk monitoring pengobatan karena membutuhkan waktu lama (2 tahun) untuk melihat perbedaan gambaran massa tulang. Analisis pertanda tulang dapat memberikan gambaran proses remodeling yang sedang terjadi dalam waktu yang lebih singkat (3 – 6 bulan). Artinya analisis pertanda tulang dapat memantau dan menilai respons pengobatan, prognosis penderita dengan risiko osteoporosis, mencari penyebab berkurangnya tulang secara cepat, memilih pengobatan yang sesuai, memantau pasien dengan pengobatan kortikosteroid dan mempelajari patogenesis osteoporosis. Dalam tulisan ini akan diuraikan beberapa analisis pertanda tulang seperti alkaline phosphatase (ALP), osteocalcin, P1-NP dan ß-CrossLaps dan kegunaannya pada tatalaksana osteoporosis.

Article Details

Issue

Vol. 26 No. 3 (2007)

Section

Review Article

The journal allows the authors to hold the copyright without restrictions and allow the authors to retain publishing rights without restrictions.

How to Cite

Peran pertanda tulang dalam serum pada tatalaksana osteoporosis. (2007). Universa Medicina, 26(3), 152-159. https://doi.org/10.18051/UnivMed.2007.v26.152-159

References

Mauck K, Clarke BL. Diagnosis, screening, prevention and treatment of osteoporosis. Mayo Clin Proc 2006; 81: 662-72.

Rachman IA. Menopause, osteoporosis dan terapi sulih hormon, pada Simposium Pendidikan berkesinambungan Patologi Klinik 2005, Jakarta 2005;1–28.

Suryaatmadja M. Peran pertanda tulang pada pengelolaan osteoporosis. Simposium Pendidikan berkesinambungan Patologi klinik 2005, Jakarta 2005; 29–41.

Endres DB, Rude RK. Mineral and bone metabolisme (Bab 4) from Burtis CA, Ashwood ER, Tietz. Textbook of clinical chemistry, Editor: NW Tietz. 2nd ed. WB Saunders co. Philadelphia 1994; 1879–973.

Kleerekoper M, Camcho P. Monitoring osteoporosis therapy. Clin Chem 2005; 51: 2227-8.

Jeannettee SP. Evaluation and assessment of osteoporosis. Am Family Physician 2001; 63: 897-904.

Genant HK. Current state of bone densitometry for osteoporosis radiographyc. Bone 1998; 18: 913-8.

Blake GM, Fogelman I. Application of bone densitometry for osteoporosis. Endocrineol Metab Clin North Am 1998; 27: 267-88.

National Osteoporosis Foundation. Physician’s guide to prevention and treatment of osteoporosis. Washington DC The foundation; 1998.

Stone KL, Lui LY, Ensrud K, Browner WS. Osteoporotic fractures research group BMD at multiple sites and risk of fracture of multiple types; Long term results from the study of osteoporotic fracture. J Bone Miner Res 2003; 18: 1947-54.

Chailurkit L, Ongphiphadhanakul B, Piaseu N, Saetung S, Rajatanavin R. Biochemical markers of bone turnover and response of bone mineral density to intervention in early postmenopausal women: an experience in clinical laboratory. J Clin Chem 2001; 47: 1083-8.

Apurva K, Srivastava, Elizabeth L, Vliet, Michael L, Maricic M, et al. Clinical use of serum and urine bone markers in the management os osteoporosis. Current Med Res Opin 2005; 21. 1015–25.

Hannon R, Blumsohn A, Naylor K, Eastell R. Response of biochemical markers of bone turnover to hormone replacement therapy: impact of biological variability. JBMR 2004; 13: 1124–35.

Clowes JA, Hannon RA, Yap TS, Hoyle NR, Blumsohn A, Eastell R. Effect of feeding on bone turnover markers and its impact on biological variability of measurements. Bone, 2002; 30: 886–90.

Blumsohn A, Naylor KE, Timm W, Eagleton AC, Hannon RA, Eastell R. Absence of marked seasonal change in bone turnover: a longitudinal and multicenter cross-sectional study. JBMR 2003; 18:1274–81.

Lomen A, Bolner A. Stability of several biochemical markers of bone metabolisme Clin Chem 2000; 46: 1200–2.

Panteghini M, Pagani F. Biological variation in bone-derived biochemical markers in serum. Scand J Clin Lab Investig 1995; 55: 609–16.

Tanko, Handsdottir, Sornay R. The use of biochemical markers Bone 2003; 6: 87–93.

Jung K, Lein M, Stephan C, Hosslin KV, Semjonow A, Loening SA et al. Comparison of 10 serum bone turnover markers in prostate carcinoma patients with bone metastatic spread: diagnostic and prognostic implications. Int J Cancer 2004; 111: 783–91.

Fink E, Cormier C, Steinmetz P, Kindermans C, Bouc L, Sourbelerbielle C. Differences in the capacity of several biochemical bone markers to assess high bone turnover in early menopause and response to alendronate therapy. Osteoporosis Int 2000; 11: 295–303.

Rosen C, Chestnut C, Mallinak N. The predictive value of biochemical markers of bone turnover for bone mineral density in early postmenopausal women treated with replacement of calcium supplementation. J. Clin Endocrinol Metab 1997; 82: 1904-10.

Reid IR, Davidson JS, Wattie D, Wu F, Lucas J, Gamble GD, et al. Comparative responses of bone turnover markers to bisphosphonate therapy in Paget’s disease of bone. Bone 2004; 11: 224–36.

Brasso K, Johansen J, Christensen J, Teisner B, Price P. High serum levels of P1NP, bone alkaline phosphatase and cancer are associated to short survival. Proc Soc Am Clin Oncol 2003.

Delmas P, Eastell R, Garnero P, Stepan J. The use of biochemical markers of bone turnover in osteoporosis. Int Osteopor Foundation 2002; Suppl 6: S2-17.

Thurairaja R, Iles RK, Jefferson K, McFarlane JP, Persad RA. Serum aminoterminal propeptide of type 1 procollagen (P1NP) in prostate cancer: a potential predictor of bone metastase and prognosticator for disease progression and survival. Urol Int 2006; 76: 67-71.

Roche diagnostics, Elecys bone marker testing, going straight for answer. 1998.

Hegedus D, Ferencz V, Lakatos PL, Meszaros S, Lakatos P, Horvath C, et al. Decreased bone density, elevated serum osteoprotegrin and beta cross-laps in Wilson disease. JBMR 2002; 17: 1961–7.

Black D, Susan L, Greenspan MD, Kristine E, Ensrud, Palermo L, et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. JBMR 2003; 349: 1207–15.

Jehle J, Zanetti A, Muser J, Hulter N, Krapf R. Partial neutralization of the acidogenic western diet with potassium citrate increases bone mass in postmenopausal women with osteopenia. J Am Soc Nephrol 2006; 7: 3213–22.

Delmas PD, Hardy P, Garbero P, Dain MP. Monitoring individual response to hormone replacement therapy with bone markers. Bone 1998; 23: 360-1.

Raven P, Christensen JO, Blaumann M, Clemensen B. Changes in biochemical markers and bone mass after withdrawl of ibandronate: prediction of bone mass changes during treatment. Bone 1998; 22: 559–64.

Commings SR, Black D, Krager KA. The effect of raloxifen on risk of breast cancer in post menopausal women. JAMA 1999; 281: 2189-98.

Libermann EA, Weiss SR, Bicoll. Effect of oral alendronate on bone mineral density and the incidence of fracture in postmenopausal osteoporosis. N Engl J Med 1995; 333: 1427-43.

Outila TA, Karkkainen MU, Seppanen RH. Dietary intake of vitamin D in premenopausal healthy vegans was insufficient to maintain concentration of serum 25 hydroxyvitamin D and intact parathyroid hormone within normal ranges during winter in Findland. J Am Diet Assoc 2000; 100: 434–41.

Cranney A, Wells G, Wilan. Metaanalysis of therapies for postmenopausal osteoporosis. Endocr Rev 2002; 23: 508–16.